Amedisys Stock Price, News & Analysis (NASDAQ:AMED)

$55.74 -1.29 (-2.26 %)
(As of 01/18/2018 02:30 PM ET)
Previous Close$57.03
Today's Range$55.69 - $57.02
52-Week Range$43.48 - $65.91
Volume408,800 shs
Average Volume380,800 shs
Market Capitalization$1.94 billion
P/E Ratio44.59
Dividend YieldN/A
Beta0.71

About Amedisys (NASDAQ:AMED)

Amedisys logoAmedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness. The Personal care segment provides patients with assistance with the essential activities of daily living.

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home Healthcare Services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Debt-to-Equity Ratio0.16%
Current Ratio1.33%
Quick Ratio1.33%

Price-To-Earnings

Trailing P/E Ratio44.592
Forward P/E Ratio24.88
P/E Growth1.22

Sales & Book Value

Annual Sales$1.44 billion
Price / Sales1.32
Cash Flow$2.11 per share
Price / Cash26.37
Book Value$13.74 per share
Price / Book4.06

Profitability

Trailing EPS$1.25
Net Income$37.26 million
Net Margins2.88%
Return on Equity14.68%
Return on Assets9.25%

Miscellaneous

Employees16,000
Outstanding Shares33,940,000

Amedisys (NASDAQ:AMED) Frequently Asked Questions

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) released its quarterly earnings data on Tuesday, November, 7th. The health services provider reported $0.56 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.54 by $0.02. The health services provider had revenue of $380.20 million for the quarter, compared to analysts' expectations of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The company's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.36 EPS. View Amedisys' Earnings History.

When will Amedisys make its next earnings announcement?

Amedisys is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Amedisys.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its third quarter earnings guidance on Tuesday, October, 24th. The company provided EPS guidance of $0.54-0.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.53. The company issued revenue guidance of ~$386 million, compared to the consensus revenue estimate of $385.46 million.

Where is Amedisys' stock going? Where will Amedisys' stock price be in 2018?

11 Wall Street analysts have issued 1-year price objectives for Amedisys' stock. Their predictions range from $54.00 to $70.00. On average, they anticipate Amedisys' stock price to reach $61.00 in the next year. View Analyst Ratings for Amedisys.

What are Wall Street analysts saying about Amedisys stock?

Here are some recent quotes from research analysts about Amedisys stock:

  • 1. According to Zacks Investment Research, "Over the past year, Amedisys has been trading above the broader industry. The company is currently exploring new opportunities in both Home Health and Hospice. At the Home Health division, the company witnessed a decline in Medicare revenues, while there was an improvement in non-Medicare revenues. At the Hospice division, the company registered strong growth across all segments. A favorable demographic trend and strategic acquisitions bode well for the company. On the flip side, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry." (1/12/2018)
  • 2. Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
  • 3. Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:

  • Paul B. Kusserow, President, Chief Executive Officer, Director (Age 55)
  • Scott G. Ginn, Chief Financial Officer, Chief Accounting Officer (Age 48)
  • Christopher T. Gerard, Chief Operating Officer (Age 50)
  • Lawrence R. Pernosky, Chief Human Resource Officer (Age 63)
  • Michael Paul North, Chief Information Officer (Age 52)
  • David B. Pearce, Chief Compliance Officer (Age 56)
  • David L. Kemmerly, General Counsel (Age 54)
  • Stephen E Seim, Chief Strategy Officer (Age 53)
  • Susan Sender, Chief Clinical Operations Officer (Age 55)
  • Donald Arthur Washburn, Non-Executive Lead Independent Chairman of the Board (Age 73)

Who owns Amedisys stock?

Amedisys' stock is owned by many different of institutional and retail investors. Top institutional investors include Copper Rock Capital Partners LLC (1.76%), Schwab Charles Investment Management Inc. (0.52%), DnB Asset Management AS (0.21%), Acadian Asset Management LLC (0.15%), Bank of Montreal Can (0.06%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, Jake L Netterville, Lawrence R Pernosky and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Who sold Amedisys stock? Who is selling Amedisys stock?

Amedisys' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Amedisys company stock in the last year include David B Pearce, Jake L Netterville, Lawrence R Pernosky and Scott G Ginn. View Insider Buying and Selling for Amedisys.

Who bought Amedisys stock? Who is buying Amedisys stock?

Amedisys' stock was acquired by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Copper Rock Capital Partners LLC, Acadian Asset Management LLC, Fox Run Management L.L.C. and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Amedisys.

How do I buy Amedisys stock?

Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of Amedisys stock can currently be purchased for approximately $55.74.

How big of a company is Amedisys?

Amedisys has a market capitalization of $1.94 billion and generates $1.44 billion in revenue each year. The health services provider earns $37.26 million in net income (profit) each year or $1.25 on an earnings per share basis. Amedisys employs 16,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


MarketBeat Community Rating for Amedisys (AMED)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  191 (Thanks for Voting!)
Underperform Votes:  358 (Thanks for Voting!)
Total Votes:  549
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amedisys (NASDAQ:AMED) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 2.552.552.402.63
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $61.00$61.00$56.20$58.29
Price Target Upside: 15.79% upside15.79% upside15.57% upside2.71% downside

Amedisys (NASDAQ:AMED) Consensus Price Target History

Price Target History for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ:AMED) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017William BlairReiterated RatingOutperformN/AView Rating Details
11/10/2017SunTrust BanksReiterated RatingBuy$70.00N/AView Rating Details
11/10/2017Robert W. BairdBoost Price TargetNeutral$50.00 -> $60.00N/AView Rating Details
11/9/2017Craig HallumReiterated RatingBuy$55.00 -> $68.00N/AView Rating Details
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform -> Sector Perform$56.00 -> $62.00N/AView Rating Details
11/9/2017BenchmarkReiterated RatingBuy -> HoldN/AView Rating Details
11/8/2017MizuhoReiterated RatingBuy$55.00 -> $65.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$60.00N/AView Rating Details
9/15/2017OppenheimerReiterated RatingBuy$60.00LowView Rating Details
8/21/2017Bank of AmericaInitiated CoverageNeutral -> Neutral$55.00LowView Rating Details
5/4/2017StephensBoost Price TargetEqual Weight$50.00 -> $54.00LowView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Amedisys (NASDAQ:AMED) Earnings History and Estimates Chart

Earnings by Quarter for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ AMED) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$0.58N/AView Earnings Details
11/7/2017Q3 2017$0.54$0.56$384.59 million$380.20 millionViewN/AView Earnings Details
7/26/2017Q2 2017$0.50$0.62$380.80 million$378.80 millionViewN/AView Earnings Details
5/2/2017Q1 2017$0.41$0.47$370.03 million$370.46 millionViewListenView Earnings Details
2/28/2017Q4 2016$0.39$0.44$368.14 million$366.30 millionViewN/AView Earnings Details
11/3/2016Q3$0.36$0.36$361.08 million$361.60 millionViewListenView Earnings Details
8/2/2016Q2$0.42$0.42$353.07 million$360.00 millionViewListenView Earnings Details
5/3/2016Q1$0.33$0.33$337.07 million$348.80 millionViewListenView Earnings Details
3/8/2016Q415$0.35$0.40$322.67 million$338.37 millionViewListenView Earnings Details
11/5/2015Q315$0.34$0.34$312.22 million$326.50 millionViewListenView Earnings Details
7/29/2015Q215$0.33$0.43$307.11 million$314.20 millionViewListenView Earnings Details
4/29/2015Q115$0.20$0.30$300.17 million$301.60 millionViewListenView Earnings Details
3/4/2015Q414$0.27$0.27$301.62 million$300.50 millionViewListenView Earnings Details
10/29/2014Q314$0.17$0.28$299.26 million$300.30 millionViewListenView Earnings Details
7/30/2014Q214$0.17$0.25$298.90 million$305.00 millionViewListenView Earnings Details
5/8/2014Q114($0.06)($0.07)$301.89 million$298.74 millionViewListenView Earnings Details
3/12/2014Q413($0.01)($0.05)$295.02 million$303.50 millionViewListenView Earnings Details
11/12/2013Q313$0.13$0.06$314.30 million$301.64 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.10$0.06$328.02 million$313.10 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.18$0.13$361.41 million$339.20 millionViewListenView Earnings Details
3/12/2013Q4 2012$0.22$0.24$373.31 million$632.90 millionViewListenView Earnings Details
11/6/2012Q312$0.27$0.33$379.97 million$375.62 millionViewN/AView Earnings Details
8/7/2012$0.24$0.27ViewN/AView Earnings Details
5/8/2012$0.22$0.22ViewN/AView Earnings Details
2/28/2012$0.29$0.25ViewN/AView Earnings Details
11/1/2011$0.50$0.36ViewN/AView Earnings Details
8/2/2011$0.69$0.75ViewN/AView Earnings Details
4/26/2011$0.66$0.53ViewN/AView Earnings Details
2/22/2011$0.91$0.77ViewN/AView Earnings Details
10/26/2010Q3 2010$0.91$0.89ViewN/AView Earnings Details
8/9/2010Q2 2010$1.17$1.13ViewN/AView Earnings Details
4/27/2010Q1 2010$1.28$1.29ViewN/AView Earnings Details
2/23/2010Q4 2009$1.32$1.35ViewN/AView Earnings Details
10/27/2009Q3 2009$1.27$1.29ViewN/AView Earnings Details
7/28/2009Q2 2009$1.02$1.27ViewN/AView Earnings Details
4/28/2009Q1 2009$0.97$0.99ViewN/AView Earnings Details
2/17/2009Q4 2008$0.91$0.98ViewN/AView Earnings Details
10/28/2008Q3 2008$0.82$0.89ViewN/AView Earnings Details
7/29/2008Q2 2008$0.68$0.76ViewN/AView Earnings Details
4/30/2008Q1 2008$0.57$0.62ViewN/AView Earnings Details
2/27/2008Q4 2007$0.60$0.63ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Amedisys (NASDAQ:AMED) Earnings Estimates

2018 EPS Consensus Estimate: $2.54
2019 EPS Consensus Estimate: $2.82
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.55$0.59$0.57
Q2 20182$0.63$0.63$0.63
Q3 20182$0.64$0.67$0.66
Q4 20182$0.67$0.70$0.69
Q1 20192$0.63$0.68$0.66
Q2 20192$0.71$0.71$0.71
Q3 20191$0.71$0.71$0.71
Q4 20191$0.74$0.74$0.74
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Amedisys (NASDAQ:AMED)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Amedisys (NASDAQ AMED) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 94.50%
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Amedisys (NASDAQ AMED) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/8/2017David B PearceInsiderSell1,000$50.00$50,000.0010,488View SEC Filing  
8/3/2017Bruce D PerkinsDirectorBuy2,000$46.60$93,200.0015,825View SEC Filing  
5/25/2017Bruce D PerkinsDirectorBuy500$59.69$29,845.0013,331View SEC Filing  
5/12/2017Jake L NettervilleDirectorSell10,000$60.00$600,000.0077,499View SEC Filing  
5/10/2017Lawrence R PernoskyInsiderSell11,500$58.97$678,155.0030,093View SEC Filing  
5/9/2017Lawrence R PernoskyInsiderSell11,500$58.78$675,970.0030,093View SEC Filing  
5/8/2017Scott G GinnInsiderSell23,828$58.62$1,396,797.3613,018View SEC Filing  
5/13/2016Bruce D PerkinsDirectorBuy1,000$50.21$50,210.0010,354View SEC Filing  
5/11/2016Scott G GinnInsiderSell6,000$51.62$309,720.0048,009View SEC Filing  
11/2/2015North Tide Capital, LlcMajor ShareholderSell277,720$39.79$11,050,478.80View SEC Filing  
10/28/2015North Tide Capital, LlcMajor ShareholderSell191,400$39.86$7,629,204.00View SEC Filing  
10/26/2015North Tide Capital, LlcMajor ShareholderSell56,400$39.32$2,217,648.00View SEC Filing  
8/18/2015Donald A WashburnDirectorSell20,000$45.51$910,200.00View SEC Filing  
3/13/2015Jeffrey D JeterInsiderSell11,264$27.02$304,353.28View SEC Filing  
3/13/2015Peter RicchiutiDirectorSell2,003$27.25$54,581.75View SEC Filing  
8/5/2014Jeffrey D JeterInsiderSell2,500$21.80$54,500.00View SEC Filing  
5/8/2014North Tide Capital, Llcmajor shareholderBuy500,000$13.90$6,950,000.00View SEC Filing  
5/1/2014North Tide Capital, Llcmajor shareholderBuy150,000$13.54$2,031,000.00View SEC Filing  
11/21/2013Kkr Asset Management Llcmajor shareholderBuy425,515$14.48$6,161,457.20View SEC Filing  
11/15/2013David BuceyGeneral CounselSell8,290$13.95$115,645.5013,057View SEC Filing  
11/14/2013Kkr Asset Management Llcmajor shareholderBuy946,500$13.89$13,146,885.00View SEC Filing  
10/30/2013Kkr Asset Management LlcMajor ShareholderBuy29,615$15.94$472,063.10View SEC Filing  
10/22/2013Kkr Asset Management LlcMajor ShareholderBuy186,013$17.55$3,264,528.15View SEC Filing  
10/18/2013Kkr Asset Management LlcMajor ShareholderBuy12,652$17.95$227,103.40View SEC Filing  
7/3/2013Linda J HallDirectorSell1,721$10.65$18,328.65View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amedisys (NASDAQ AMED) News Headlines

Source:
DateHeadline
Q1 2019 Earnings Forecast for Amedisys Inc (AMED) Issued By OppenheimerQ1 2019 Earnings Forecast for Amedisys Inc (AMED) Issued By Oppenheimer
www.americanbankingnews.com - January 17 at 10:44 PM
Amedisys (AMED) Upgraded to Buy by Zacks Investment ResearchAmedisys (AMED) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - January 12 at 3:38 PM
Interesting AMED Put And Call Options For February 16thInteresting AMED Put And Call Options For February 16th
www.nasdaq.com - January 12 at 3:30 PM
Form 8-K AMEDISYS INC For: Jan 10Form 8-K AMEDISYS INC For: Jan 10
www.streetinsider.com - January 10 at 3:32 PM
Amedisys Inc (AMED) Receives Consensus Recommendation of "Buy" from BrokeragesAmedisys Inc (AMED) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 9 at 2:08 PM
$394.96 Million in Sales Expected for Amedisys Inc (AMED) This Quarter$394.96 Million in Sales Expected for Amedisys Inc (AMED) This Quarter
www.americanbankingnews.com - January 8 at 2:26 AM
Amedisys (AMED) Announces Collaborative Partnership with myNEXUSAmedisys (AMED) Announces Collaborative Partnership with myNEXUS
www.streetinsider.com - January 5 at 10:44 AM
Amedisys Forges Collaborative Partnership with myNEXUS®Amedisys Forges Collaborative Partnership with myNEXUS®
finance.yahoo.com - January 4 at 11:21 AM
4 Reasons Why Envision Healthcare (EVHC) Looks Dull4 Reasons Why Envision Healthcare (EVHC) Looks Dull
finance.yahoo.com - December 27 at 1:28 PM
Cerner Gains Momentum in HCIT Space Amid Tough CompetitionCerner Gains Momentum in HCIT Space Amid Tough Competition
finance.yahoo.com - December 27 at 1:28 PM
Amedisys Inc (AMED) Expected to Announce Quarterly Sales of $394.96 MillionAmedisys Inc (AMED) Expected to Announce Quarterly Sales of $394.96 Million
www.americanbankingnews.com - December 23 at 5:58 AM
3 Health Care Stocks With M&A Potential In 20183 Health Care Stocks With M&A Potential In 2018
finance.yahoo.com - December 22 at 4:10 PM
Amedisys, Inc. breached its 50 day moving average in a Bearish Manner : AMED-US : December 21, 2017Amedisys, Inc. breached its 50 day moving average in a Bearish Manner : AMED-US : December 21, 2017
finance.yahoo.com - December 21 at 10:33 AM
Amedisys (AMED) Banks on Personal Care Amid Margin WoesAmedisys (AMED) Banks on Personal Care Amid Margin Woes
finance.yahoo.com - December 19 at 11:00 AM
Amedisys Inc (AMED) Receives Average Recommendation of "Buy" from BrokeragesAmedisys Inc (AMED) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 15 at 10:06 AM
Amedisys, Inc. breached its 50 day moving average in a Bearish Manner : AMED-US : December 6, 2017Amedisys, Inc. breached its 50 day moving average in a Bearish Manner : AMED-US : December 6, 2017
finance.yahoo.com - December 6 at 11:45 AM
 Analysts Expect Amedisys Inc (AMED) Will Post Quarterly Sales of $394.96 Million Analysts Expect Amedisys Inc (AMED) Will Post Quarterly Sales of $394.96 Million
www.americanbankingnews.com - December 5 at 3:02 AM
$0.59 EPS Expected for Amedisys Inc (AMED) This Quarter$0.59 EPS Expected for Amedisys Inc (AMED) This Quarter
www.americanbankingnews.com - December 3 at 5:28 PM
Amedisys (AMED) Shares Cross Below 200 DMAAmedisys (AMED) Shares Cross Below 200 DMA
www.nasdaq.com - November 28 at 3:31 PM
ETFs with exposure to Amedisys, Inc. : November 27, 2017ETFs with exposure to Amedisys, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:20 PM
Here's Why You Should Add Amedisys (AMED) to Your PortfolioHere's Why You Should Add Amedisys (AMED) to Your Portfolio
finance.yahoo.com - November 24 at 11:46 AM
Amedisys Inc (AMED) Coverage Initiated by Analysts at William BlairAmedisys Inc (AMED) Coverage Initiated by Analysts at William Blair
www.americanbankingnews.com - November 21 at 5:40 PM
Amedisys Inc (AMED) Receives Consensus Recommendation of "Hold" from BrokeragesAmedisys Inc (AMED) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 9:16 AM
$394.93 Million in Sales Expected for Amedisys Inc (AMED) This Quarter$394.93 Million in Sales Expected for Amedisys Inc (AMED) This Quarter
www.americanbankingnews.com - November 17 at 10:38 AM
ETFs with exposure to Amedisys, Inc. : November 14, 2017ETFs with exposure to Amedisys, Inc. : November 14, 2017
finance.yahoo.com - November 14 at 4:19 PM
Amedisys, Inc. :AMED-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Amedisys, Inc. :AMED-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 14 at 2:43 AM
Robert W. Baird Increases Amedisys Inc (AMED) Price Target to $60.00Robert W. Baird Increases Amedisys Inc (AMED) Price Target to $60.00
www.americanbankingnews.com - November 12 at 10:30 AM
Amedisys Inc (AMED) Earns "Buy" Rating from SunTrust Banks, Inc.Amedisys Inc (AMED) Earns "Buy" Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - November 11 at 4:56 PM
AMEDISYS Inc 2017 Q3 - Results - Earnings Call SlidesAMEDISYS Inc 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 11 at 9:01 AM
Stocks Showing Rising Market Leadership: Amedisys Earns 85 RS RatingStocks Showing Rising Market Leadership: Amedisys Earns 85 RS Rating
finance.yahoo.com - November 10 at 7:25 PM
Edited Transcript of AMED earnings conference call or presentation 8-Nov-17 4:00pm GMTEdited Transcript of AMED earnings conference call or presentation 8-Nov-17 4:00pm GMT
finance.yahoo.com - November 10 at 7:25 PM
2017 HomeCare Elite Recognizes Top Amedisys Care Centers Nationwide2017 HomeCare Elite Recognizes Top Amedisys Care Centers Nationwide
www.nasdaq.com - November 10 at 2:23 PM
FY2017 Earnings Estimate for Amedisys Inc (AMED) Issued By Oppenheimer HoldingsFY2017 Earnings Estimate for Amedisys Inc (AMED) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 10 at 8:34 AM
SunTrust Banks Comments on Amedisys Incs FY2017 Earnings (AMED)SunTrust Banks Comments on Amedisys Inc's FY2017 Earnings (AMED)
www.americanbankingnews.com - November 10 at 8:34 AM
Amedisys Inc (AMED) Receives "Buy" Rating from Craig HallumAmedisys Inc (AMED) Receives "Buy" Rating from Craig Hallum
www.americanbankingnews.com - November 9 at 11:55 AM
FY2017 Earnings Forecast for Amedisys Inc Issued By Jefferies Group (AMED)FY2017 Earnings Forecast for Amedisys Inc Issued By Jefferies Group (AMED)
www.americanbankingnews.com - November 9 at 8:31 AM
Amedisys (AMED) Tops Q3 EPS by 2c, Miss on RevenuesAmedisys (AMED) Tops Q3 EPS by 2c, Miss on Revenues
www.streetinsider.com - November 7 at 10:35 PM
Amedisys beats 3Q profit forecastsAmedisys beats 3Q profit forecasts
finance.yahoo.com - November 7 at 10:35 PM
Amedisys Inc (AMED) Posts Quarterly  Earnings Results, Beats Expectations By $0.02 EPSAmedisys Inc (AMED) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - November 7 at 6:54 PM
Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim ViewEnvision Healthcare Hits 52-Week Low on Q3 Loss, Grim View
finance.yahoo.com - November 7 at 5:32 PM
Amedisys Reports Third Quarter 2017 Financial ResultsAmedisys Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 5:32 PM
Stocks With Rising Relative Strength: AmedisysStocks With Rising Relative Strength: Amedisys
finance.yahoo.com - November 6 at 10:00 PM
Amedisys, Inc. – Value Analysis (NASDAQ:AMED) : November 6, 2017Amedisys, Inc. – Value Analysis (NASDAQ:AMED) : November 6, 2017
finance.yahoo.com - November 6 at 10:00 PM
Amedisys, Inc.: Strong price momentum but will it sustain?Amedisys, Inc.: Strong price momentum but will it sustain?
finance.yahoo.com - November 3 at 3:52 PM
Amedisys, Inc. breached its 50 day moving average in a Bullish Manner : AMED-US : November 3, 2017Amedisys, Inc. breached its 50 day moving average in a Bullish Manner : AMED-US : November 3, 2017
finance.yahoo.com - November 3 at 9:36 AM
$385.37 Million in Sales Expected for Amedisys Inc (AMED) This Quarter$385.37 Million in Sales Expected for Amedisys Inc (AMED) This Quarter
www.americanbankingnews.com - October 27 at 6:40 AM
BRIEF-Amedisys sees Q3 net service revenues of about $380 mlnBRIEF-Amedisys sees Q3 net service revenues of about $380 mln
www.reuters.com - October 26 at 10:53 AM
Amedisys (AMED) Reports Prelim. Q3 ResultsAmedisys (AMED) Reports Prelim. Q3 Results
www.streetinsider.com - October 26 at 10:53 AM
Amedisys Inc (AMED) Given Consensus Rating of "Hold" by AnalystsAmedisys Inc (AMED) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - October 26 at 9:50 AM
Q3 2017 EPS Estimates for Amedisys Inc (AMED) Lifted by AnalystQ3 2017 EPS Estimates for Amedisys Inc (AMED) Lifted by Analyst
www.americanbankingnews.com - October 26 at 8:34 AM

SEC Filings

Amedisys (NASDAQ:AMED) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amedisys (NASDAQ:AMED) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amedisys (NASDAQ AMED) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.